第一财经记者从多方了解到,由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周获批。 截至6月26日收盘,信达生物(1801.HK)股价下跌约5%。信达生物此前公开表示,玛仕度肽减重和降糖两项适应症都有望于今年年内获批。 玛仕度肽是全球首个GCG/GLP-1双受体激动减重药物,获批后有望打破目前由跨国巨头诺和诺德、礼来主导的全球减重药领域双雄争霸的格局,并有望...
Source Link第一财经记者从多方了解到,由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周获批。 截至6月26日收盘,信达生物(1801.HK)股价下跌约5%。信达生物此前公开表示,玛仕度肽减重和降糖两项适应症都有望于今年年内获批。 玛仕度肽是全球首个GCG/GLP-1双受体激动减重药物,获批后有望打破目前由跨国巨头诺和诺德、礼来主导的全球减重药领域双雄争霸的格局,并有望...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.